
TLGTQ
Healthcare · Pharmaceuticals · $18,563 market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 16, 2021 | Before the open | -0.13 | -0.14 | -7.7% |
| May 4, 2021 | Before the open | -2.11 | 0.03 | +101.4% |
| Jan 4, 2021 | Time not confirmed | — | -0.08 | — |
| Dec 31, 2020 | After the close | -1.48 | -0.42 | +71.6% |
| Aug 19, 2020 | Before the open | -1.70 | -1.54 | +9.4% |
| Apr 8, 2020 | Before the open | -0.17 | -1.70 | -900.0% |
| Nov 4, 2019 | After the close | -0.17 | -0.40 | -135.3% |
| Aug 5, 2019 | After the close | -0.35 | -0.40 | -14.3% |
| May 6, 2019 | After the close | -0.67 | -0.90 | -34.3% |
| Mar 18, 2019 | Before the open | -0.25 | -1.80 | -620.0% |
| Nov 13, 2018 | After the close | -0.28 | -0.70 | -150.0% |
| Aug 8, 2018 | After the close | -0.26 | -0.70 | -169.2% |
| May 8, 2018 | Before the open | -0.03 |
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the…
| -0.04 |
| -33.3% |
| Mar 15, 2018 | After the close | -0.10 | -0.06 | +40.0% |